Cracking the Code: How to Stop Pancreatic Cancer's Deadly Spread
"New Research Reveals Potential Targets for Disrupting Pancreatic Cancer Metastasis and Improving Treatment"
Pancreatic cancer is one of the deadliest forms of cancer, notorious for its aggressive spread and limited treatment options. The majority of patients face a grim prognosis, highlighting the urgent need for innovative therapeutic strategies.
Two recent studies presented at a major cancer conference offer promising insights into tackling this disease. One focuses on inhibiting a specific protein that promotes cancer cell survival and proliferation, while the other explores how to disrupt the process by which pancreatic cancer cells spread to other parts of the body.
This article breaks down these findings, explaining how they could lead to more effective treatments and improved outcomes for patients with pancreatic cancer.
Pancreatic Cancer: Prevalence and Molecular Context
SEER estimates that about 1.7 percent of men and women will be diagnosed with pancreatic cancer during their lifetime, based on 2021–2023 data; an estimated 113,931 people in the United States were living with it in 2023. Research on pancreatic cancer has also examined how Ras/ERK signaling and ribosomal protein S6 phosphorylation affect translation: one study reported that RSK links Ras/ERK signaling to the translational machinery through an mTOR-independent pathway. Another study found that pancreatic cancer precursor lesions were greatly reduced in rpS6 phosphorylation-deficient mice, suggesting a role for rpS6 phosphorylation in Kras-induced DNA damage and p53-mediated tumor suppression.
Understanding Pancreatic Cancer’s Natural History
Research into pancreatic ductal adenocarcinoma’s natural history has addressed its cell of origin, initiating somatic mutations, altered pathways, biological heterogeneity, and relationship between primary tumors and metastases. One review reports that metastasis is a common feature, with up to 90% of patients having metastatic disease at death. The Lustgarten Foundation’s timeline documents research milestones and advances in the effort against pancreatic cancer.
Targeting P90-RSK: A Synthetic Lethal Approach
One study homes in on the protein p90 ribosomal S6 kinase (RSK), particularly the RSK3 variant, as a potential target for therapy. The research team recognized that directly inhibiting RSK3 has proven difficult due to a lack of selective and effective inhibitors. Therefore, they pursued a "synthetic lethal" strategy. This approach exploits the reliance of cancer cells on specific proteins or pathways, meaning that inhibiting RSK3 is only lethal to cancer cells when another key pathway, such as the EGFR pathway, is also blocked.
- Compound Screening: Researchers screened 40,000 compounds to identify those that, combined with EGFR inhibition, best reduced cancer cell viability.
- RSK3 Inhibition: Selected compounds effectively inhibited RSK3, decreasing phosphorylation of downstream targets.
- Reduced Proliferation: Treatment with the identified inhibitors led to a significant reduction in the proliferation and viability of pancreatic cancer cells.
- Apoptosis Induction: The inhibitors induced apoptosis (programmed cell death) in cancer cells, showing a synergistic effect when combined with the EGF signaling inhibitor Erlotinib.
Why Targeted Strategies Can Fall Short
The effectiveness of inhibitors aimed at distinct oncogenic KRAS effector pathways may vary across tumor types; the cited review notes that KRAS engages different downstream effectors in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. In pancreatic cancer cells, experiments found that recombinant HSP90α could still promote changes associated with epithelial-to-mesenchymal transition in LRP1-knockdown Capan-2 cells, indicating that signaling beyond the LRP1-AKT-dependent pathway may be involved. Drug development also faces practical barriers: BI-D1870 was challenging to formulate for in vivo administration and had a poor pharmacokinetic profile.
Disrupting EMT: Halting the Spread of Pancreatic Cancer
The second study investigates the epithelial-to-mesenchymal transition (EMT), a process by which cancer cells transform and gain the ability to invade other tissues and organs. EMT is a critical step in metastasis, the primary driver of cancer-related deaths.
Real-World Outcomes and Treatment Variation
A study described as a real-world analysis in Europe examines treatment sequences and prognostic and predictive factors in metastatic pancreatic ductal adenocarcinoma using univariate and multivariate analyses. Another study, published February 25, 2026, aimed to evaluate real-world outcomes following adjuvant chemotherapy. Its source notes that pancreatic cancer remains challenging to diagnose and treat and that management and outcomes vary considerably by region. The provided summaries do not report the studies’ outcome figures or conclusions.
Researchers found that pancreatic ductal adenocarcinoma (PDAC) cells display substantial heterogeneity in their EMT marker expression and ability to undergo EMT. Even cells with the same genetic makeup can exhibit different responses to EMT-inducing signals, suggesting that tumors with similar genetic backgrounds could evolve different routes toward metastasis.
This discovery highlights the complexity of pancreatic cancer and suggests that a more personalized approach is needed to optimize treatment options. By understanding the specific mechanisms driving EMT in individual patients, clinicians may be able to develop more effective strategies to prevent metastasis and improve outcomes.